With the first quarter of 2020 just setting a fresh record for biopharma venture funding in the U.S., highlighting an unprecedented level of innovation and expectations for sustained value creation. Though we could see some reprioritization among early-stage investments with the crisis, with modalities such as cell and gene therapy, antisense oligonucleotides, and RNA inter-ference technologies breaking full steam into the commercial spotlight, we do not foresee any major changes to the innovative environment.
We are witnessing an unprecedented level of cooperation and speed in this pandemic from basic science to even manufacturing as 70+ biotechs rapidly shift focus toward the common goal of developing a treatment and vaccine. Again and again, we have heard from management and doctors the unprecedented level of communication and access available at all levels. Partnerships are being created at record speeds to immediately join the hunt—sometimes even with deal-term negotiations ongoing. It took our community roughly three months from viral genetic-sequence selection to the first human study for vaccine development—a record milestone nearly 17 months ahead of the vaccine-development timeline for SARS (2003) and, most recently, several weeks ahead of Zika virus (2016) development.
SPL Price at posting:
$1.12 Sentiment: Buy Disclosure: Held
are witnessing an unprecedented level of cooperation and speed in this pandemic from basic science to even manufacturing as 70+ biotechs rapidly shift focus toward the common goal of developing a treatment and vaccine. Again and again, we have heard from management and doctors the unprecedented level of communication and access available at all levels. Partnerships are being created at record speeds to immediately join the hunt—sometimes even with deal-term negotiations ongoing. It took our community roughly three months from viral genetic-sequence selection to the first human study for vaccine development—a record milestone nearly 17 months ahead of the vaccine-development timeline for SARS (2003) and, most recently, several weeks ahead of Zika virus (2016) development.
